Venus Remedies Limited, an illustrious pharmaceutical company known for its research-driven approach, has recently clinched marketing authorization for meropenem in Spain. This development paves the way for the launch of the antibiotic, which is critical in the fight against severe infections, in the Spanish market.
Meropenem is a last-resort antibiotic in the carbapenem class. It’s mainly used in hospital intensive care units to treat patients with life-threatening infections. The drug holds a significant place in the offerings of Venus Remedies, contributing to 40% of its total sales.
Saransh Chaudhary, the President of Global Critical Care at Venus Remedies, spoke on the importance of this milestone. He noted that the authorization highlights the company’s exceptional manufacturing capabilities and dedication to developing quality pharmaceuticals.
Scheduled for a December launch, Venus Remedies aims to corner a 10% share of the meropenem market in Spain, which is valued at $6.34 million. This move is expected to bolster the company’s stature in the European pharmaceutical landscape.
Venus Remedies has successfully launched meropenem in many European markets, either under its own brand or through alliances. The company has amassed over 120 marketing authorizations for meropenem globally.
Akshansh Chaudhary, the Executive Director of Venus Remedies, stated that the company expects a significant boost in turnover due to marketing approvals. “We are negotiating more strategic alliances with multinational companies in regulated markets,” he added.
Venus Remedies’ manufacturing facilities can produce 24 million units of meropenem annually on a single-shift basis. Presently, it operates at 60% of its capacity, indicating significant scalability to meet future demands.
Venus Remedies’ procurement of marketing authorization for meropenem in Spain is a landmark achievement. This not only attests to its manufacturing prowess but also signals its resolve to play a more significant role in the global pharmaceutical domain.
